Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Work In Process: 2022-2025

Historic Work In Process for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to $12.9 million.

  • Axsome Therapeutics' Work In Process rose 56.87% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year increase of 56.87%. This contributed to the annual value of $7.7 million for FY2024, which is 24.92% down from last year.
  • Latest data reveals that Axsome Therapeutics reported Work In Process of $12.9 million as of Q3 2025, which was up 72.38% from $7.5 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Work In Process high stood at $14.0 million for Q4 2022, and its period low was $6.8 million during Q1 2025.
  • In the last 3 years, Axsome Therapeutics' Work In Process had a median value of $10.3 million in 2023 and averaged $9.7 million.
  • Within the past 5 years, the most significant YoY rise in Axsome Therapeutics' Work In Process was 56.87% (2025), while the steepest drop was 37.64% (2025).
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Work In Process stood at $14.0 million in 2022, then dropped by 26.34% to $10.3 million in 2023, then fell by 24.92% to $7.7 million in 2024, then soared by 56.87% to $12.9 million in 2025.
  • Its last three reported values are $12.9 million in Q3 2025, $7.5 million for Q2 2025, and $6.8 million during Q1 2025.